| Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS T Miller, M Cudkowicz, PJ Shaw, PM Andersen, N Atassi, RC Bucelli, ... New England Journal of Medicine 383 (2), 109-119, 2020 | 432 | 2020 |
| The PRO-ACT database: design, initial analyses, and predictive features N Atassi, J Berry, A Shui, N Zach, A Sherman, E Sinani, J Walker, ... Neurology 83 (19), 1719-1725, 2014 | 264 | 2014 |
| Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28 NR Zürcher, ML Loggia, R Lawson, DB Chonde, D Izquierdo-Garcia, ... NeuroImage: Clinical 7, 409-414, 2015 | 218 | 2015 |
| Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) S Paganoni, EA Macklin, A Lee, A Murphy, J Chang, A Zipf, M Cudkowicz, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15 (5-6), 453-456, 2014 | 218 | 2014 |
| Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia OH Tam, NV Rozhkov, R Shaw, D Kim, I Hubbard, S Fennessey, N Propp, ... Cell reports 29 (5), 1164-1177. e5, 2019 | 216 | 2019 |
| Transplantation of spinal cord–derived neural stem cells for ALS: analysis of phase 1 and 2 trials JD Glass, VS Hertzberg, NM Boulis, J Riley, T Federici, M Polak, ... Neurology 87 (4), 392-400, 2016 | 150 | 2016 |
| Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS M Benatar, J Wuu, PM Andersen, N Atassi, W David, M Cudkowicz, ... Neurology 90 (7), e565-e574, 2018 | 129 | 2018 |
| ALS biomarkers for therapy development: state of the field and future directions M Benatar, K Boylan, A Jeromin, SB Rutkove, J Berry, N Atassi, L Bruijn Muscle & nerve 53 (2), 169-182, 2016 | 121 | 2016 |
| Depression in amyotrophic lateral sclerosis N Atassi, A Cook, CME Pineda, P Yerramilli-Rao, D Pulley, M Cudkowicz Amyotrophic Lateral Sclerosis 12 (2), 109-112, 2011 | 115 | 2011 |
| Randomized phase 2 trial of NP001, a novel immune regulator: Safety and early efficacy in ALS RG Miller, G Block, JS Katz, RJ Barohn, V Gopalakrishnan, M Cudkowicz, ... Neuroimmunology & Neuroinflammation 2 (3), e100, 2015 | 100 | 2015 |
| Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis MJ Alshikho, NR Zürcher, ML Loggia, P Cernasov, DB Chonde, ... Neurology 87 (24), 2554-2561, 2016 | 98 | 2016 |
| A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression MD Weiss, EA Macklin, Z Simmons, AS Knox, DJ Greenblatt, N Atassi, ... Neurology 86 (16), 1474-1481, 2016 | 97 | 2016 |
| Integrated magnetic resonance imaging and [11C]‐PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis MJ Alshikho, NR Zürcher, ML Loggia, P Cernasov, B Reynolds, ... Annals of neurology 83 (6), 1186-1197, 2018 | 96 | 2018 |
| Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial BJ Wainger, EA Macklin, S Vucic, CE McIlduff, S Paganoni, NJ Maragakis, ... JAMA neurology 78 (2), 186-196, 2021 | 95 | 2021 |
| Defining SOD1 ALS natural history to guide therapeutic clinical trial design T Bali, W Self, J Liu, T Siddique, LH Wang, TD Bird, E Ratti, N Atassi, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (2), 99-105, 2017 | 81 | 2017 |
| A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis LL Clawson, M Cudkowicz, L Krivickas, BR Brooks, M Sanjak, P Allred, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19 (3-4), 250-258, 2018 | 69 | 2018 |
| Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis R Dewan, R Chia, J Ding, RA Hickman, TD Stein, Y Abramzon, S Ahmed, ... Neuron 109 (3), 448-460. e4, 2021 | 66 | 2021 |
| Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach R Kueffner, N Zach, M Bronfeld, R Norel, N Atassi, V Balagurusamy, ... Scientific reports 9 (1), 690, 2019 | 66 | 2019 |
| Analysis of start-up, retention, and adherence in ALS clinical trials N Atassi, P Yerramilli-Rao, J Szymonifka, H Yu, M Kearney, D Grasso, ... Neurology 81 (15), 1350-1355, 2013 | 58 | 2013 |
| Head-to-head comparison of 11C-PBR28 and 18F-GE180 for quantification of the translocator protein in the human brain P Zanotti-Fregonara, B Pascual, G Rizzo, M Yu, N Pal, D Beers, R Carter, ... Journal of Nuclear Medicine 59 (8), 1260-1266, 2018 | 57 | 2018 |
